Hemogenyx Pharmaceuticals (LON:HEMO) Shares Up 5.6% – What’s Next?

Shares of Hemogenyx Pharmaceuticals Plc (LON:HEMO) shot up 5.6% on Monday. The company traded as high as GBX 700 and last traded at GBX 695. 19,073 shares traded hands during mid-day trading, a decline of 20% from the average session volume of 23,988 shares. The stock had previously closed at GBX 658.

Hemogenyx Pharmaceuticals Stock Performance

The stock has a market capitalization of £47.93 million, a P/E ratio of -5.31 and a beta of 1.49. The company’s 50-day moving average is GBX 566.94 and its two-hundred day moving average is GBX 692.16. The company has a current ratio of 4.04, a quick ratio of 6.72 and a debt-to-equity ratio of 42.86.

Hemogenyx Pharmaceuticals (LON:HEMO) last posted its earnings results on Monday, September 28th. The company reported GBX (101.70) earnings per share (EPS) for the quarter.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.